Clinical Trial Update: A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the biological effects of AZD9833 in women with ER-positive, HER2-negative primary breast cancer has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• AZD9833 (AZD9833)

Snippet

Sponsor: AstraZeneca | Conditions: HER2-negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-01-24